Identification of dysregulated genes in patients with multiple sclerosis
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsFernando Dangond, Daehee Hwang
Life of this patent
Estimating the term…
Abstract
The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression.
Claims46
A method of predicting whether a subject is or will be afflicted with multiple sclerosis (MS) comprising:
- (a) obtaining an mRNA-containing sample from said subject;
- (b) determining expression information for one or more genes from the group consisting of phosphatidylinositol transfer protein, inducible nitric oxide synthase, CIC-1 muscle chloride channel protein, placental bikunin, receptor kinase ligand LERK-3, GATA-4, thymopoietin, transcription factor E2f-2, S-adenosylmethionine synthetase, carcinoembryonic antigen, ret transforming gene, G protein-linked receptor, GTP-binding protein RALB, tyrosine kinase Syk, T cell leukemia LERK-2, tyrosine kinase (ELK1) oncogene, transcription factor SL1, phospholipase c, gastricsin, and D13S824E locus;
- (c) comparing expression information for said selected genes with the expression information of the same genes in a subject not afflicted with MS;
- and
- (d) predicting whether said subject is or will be afflicted with MS.
A chip or wafer comprising a nucleic acid microarray, wherein said nucleic acids hybridize to target transcripts or cDNAs for phosphatidylinositol transfer protein, inducible nitric oxide synthase, CIC-1 muscle chloride channel protein, placental bikunin, receptor kinase ligand LERK-3, GATA-4, thymopoietin, transcription factor E2f-2, S-adenosylmethionine synthetase, carcinoembryonic antigen, ret transforming gene, G protein-linked receptor, GTP-binding protein RALB, tyrosine kinase Syk, T cell leukemia LERK-2, tyrosine kinase (ELK1) oncogene, transcription factor SL1, phospholipase c, gastricsin, and D13S824E locus.
A method for monitoring a therapy for multiple sclerosis comprising:
- (a) obtaining an mRNA-containing sample from a subject receiving said therapy;
- (b) determining expression information for one or more genes comprising phospatidylinositol transfer protein, inducible nitric oxide synthase, CIC-1 muscle chloride channel protein, placental bikunin, receptor kinase ligand LERK-3, GATA-4, thymopoietin, transcription factor E2f-2, S-adenosylmethionine synthetase, carcinoembryonic antigen, ret transforming gene, G protein-linked receptor, GTP-binding protein RALB, tyrosine kinase Syk, T cell leukemia LERK-2, tyrosine kinase (ELK1) oncogene, transcription factor SL1, phospholipase c, gastricsin, and D13S824E locus;
- and
- (c) comparing expression information for said selected genes with the expression information of the same genes in an MS subject not receiving said therapy.
A method for determining the efficacy of a therapy for multiple sclerosis comprising:
- (a) obtaining an mRNA-containing sample from a subject receiving said therapy;
- (b) determining expression information for one or more selected genes selected from the group consisting of skeletal muscle LIM-prot SLIM1, R kappa B, 815A9.1 myosin heavy chain, γ G2 psi from γ crystallin, thrombospondin 4, KIAA0178 (or Z97054);
- (c) comparing expression information for said one or more selected genes with the expression information of the same gene or genes in an MS subject not receiving said therapy;
- and
- (d) determining the efficacy of said therapy based on the ability of said therapy to alter the expression of said one or more genes.
A method for treating multiple sclerosis (MS) comprising administering to a subject with MS a drug that causes an increase in the level of a gene product selected from the group consisting of those genes indicated by a minus (−) sign in Tables 1-12.
A method for treating multiple sclerosis (MS) comprising administering to a subject with MS a drug that causes a decrease in the level of a gene product selected from the group consisting of those genes indicated by a plus (+) sign in Tables 1-12 and 16.
Dependencies are inferred from the claim text.